Nicolas Charloteaux - 29 Sep 2020
CureVac is developing a mRNA based prophylactic vaccine against SARS-CoV-2, funded by and in collaboration with CEPI, the Coalition for Epidemic Preparedness Innovations. On 16 March 2020, the EU Commission offered financial support to CureVac, to scale up development and production of a vaccine against the coronavirus in Europe. The support has come in form of an EU guarantee of a currently assessed EIB loan of an identical amount, in the framework of the InnovFin Infectious Disease Finance Facility under Horizon 2020.
Members area
